Q32 Bio ($QTTB) Stock Hub: Positive SIGNAL-AA 36-Week Data in Alopecia Areata

01 · Executive summary: the positive 36-week data

Q32 Bio is a clinical-stage biotechnology company whose near-term fate revolves almost entirely around a single drug, bempikibart (code name ADX-914), and a single disease, alopecia areata. Today, Monday 13 July 2026, the company reported positive 36-week topline results from Part B of the SIGNAL-AA study, the readout the market had been waiting for over several months. The primary endpoint was met, with a mean 35.3% reduction in the SALT score from baseline in the modified intent-to-treat (mITT) population, a clean safety profile and early signs of durability. A conference call with webcast and the key opinion leader Arash Mostaghimi, MD was held at 8:00 a.m. ET, corresponding to 2:00 p.m. in Italy. For a company with a single lead asset, an event like this is by definition binary; the market welcomed the data positively.

This hub is deliberately descriptive and educational. It contains no buy or sell recommendations and indicates no price targets. The goal is to put the reader in a position to understand what the data showed, how the molecule works, how the study is designed, which clinical parameters matter, the state of the balance sheet after a dense series of capital raises, and the structural risks of a single-product biotech. The full 36-week results are set out in section 03.

In short, there are five key elements. First: today’s catalyst, the 36-week readout from Part B (a Phase 2a open-label study in 33 patients with severe to very severe alopecia areata), came out positive, with the primary endpoint met and SALT-20 reached by 40.0% of patients in the mITT population (30.3% in the ITT population) at week 36. Second: the science rests on blocking the interleukin-7 receptor (IL-7Rα), which simultaneously switches off two immune signals, IL-7 and TSLP. Third: durability signals continued off-drug, with maintenance or deepening of the response in more patients, including one patient with complete hair regrowth (SALT = 0). Fourth: on the financial side, cash at the end of March was $50.8 million, then reinforced by a $55 million private placement at the end of May, with a runway guided into the first half of 2028; the company intends to advance bempikibart into a registration-directed program in the first half of 2027. Fifth, and on the risk side: dilution has been heavy and repeated, and after the sale of ADX-097 the company is effectively a single clinical-program business.

02 · Snapshot “At a glance”

The table below summarises the fundamentals of Q32 Bio as reported in the most recent official documents. These are reference numbers: cash and share count change quickly in a company that has completed several fundraising operations in a few months, so they should always be read alongside their date.

The eight stat tiles at the top of the page restate the same values in more compact form. The takeaway is that this is a small-cap biotech with a profile typical of the sector: physiological operating losses in the clinical stage, research and development spending down after the restructuring, and a cash position that funds operations for roughly a two-year horizon according to company guidance.

03 · Today’s event: positive Part B 36-week topline

On 13 July 2026 Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA study of bempikibart in alopecia areata. The company held a conference call with webcast at 8:00 a.m. ET, that is 2:00 p.m. Italian time, featuring the key opinion leader Arash Mostaghimi, MD. The link is available at app.webinar.net/m5ZoPmkRXdL and in the “Investors” section of the company website www.Q32Bio.com.^[9]

The primary endpoint was met: in the modified intent-to-treat (mITT) population the mean percentage reduction in the SALT (Severity of Alopecia Tool) score from baseline was 35.3% at week 36. Responses were observed in both severe and very severe patients. The population comprised 33 patients with severe to very severe alopecia areata (baseline SALT of 50-100) and a current episode duration of up to four years; 36.4% had been previously treated with oral JAK inhibitors.^[9]

36-week response rates

Durability, safety and pharmacology

• Durability. First signs emerged in the off-drug period, with maintenance or deepening of the response in more patients, including one patient with complete hair regrowth (SALT = 0).
• Safety. Bempikibart was generally well tolerated, consistent with prior studies and with no new safety signals: no serious adverse events (SAEs) and no treatment-related adverse events of grade 3 or higher. The most common adverse event was injection-site reaction (ISR), reported in 36.3% of patients, with an ISR incidence of 4% across all Part B administrations; all were mild and resolved without intervention, most within a day.
• PK/PD/ADA. The profile was favourable: thanks to the loading regimen, steady state was reached about 10 weeks earlier than in Part A, with negligible anti-drug antibodies (ADA).
• Next steps. Q32 Bio intends to advance bempikibart into a registration-directed program in the first half of 2027, with full Part B data to be presented at a future medical congress. Off-drug follow-up to week 52 is ongoing and enrollment in the open-label extension (OLE) continues.

04 · Who is Q32 Bio

Q32 Bio is a clinical-stage biotechnology company developing therapies aimed at restoring a healthy balance of the immune system in autoimmune and inflammatory diseases. Its stock-market history is recent and runs through a reverse merger, the mechanism by which a private company reaches a listing by combining with an already-listed shell.

The Homology Medicines merger

On 16 November 2023 the private Q32 Bio and Homology Medicines, an already-listed company, had announced a merger agreement. The transaction closed on 25 March 2024; concurrently a reverse stock split was carried out at a ratio of 1-for-18 and, the following day, on 26 March 2024, the shares began trading under the ticker QTTB on Nasdaq. In conjunction with the closing, the company completed a $42 million private placement to fund its clinical programs.^[7]

The reverse merger with Homology gave Q32 Bio access to the public market and the renaming of the company under its own brand. From that point the equity story is that of a clinical-stage biotech financing itself in the market in line with the progress of its studies.

The focus on alopecia areata after the restructuring

Over its journey Q32 Bio has had more than one program. In addition to bempikibart (ADX-914), the company was also advancing ADX-097, a complement-system program. In December 2025 Q32 Bio divested ADX-097 and, in February 2026, announced a restructuring that concentrated resources on the bempikibart program in alopecia areata. As a result, today the company is effectively focused on a single lead clinical asset: this is a crucial element for understanding the stock’s risk profile, because perceived value depends largely on the trajectory of one program.

05 · The science: bempikibart (ADX-914)

Bempikibart, also referred to by the development code ADX-914, is a monoclonal antibody that acts as a full antagonist of the alpha receptor of interleukin-7, IL-7Rα. The scientific rationale is that this receptor is a shared entry point for two distinct but related immune signals: interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). By blocking the receptor, bempikibart simultaneously interrupts both signalling pathways.

Why does this matter in alopecia areata? Alopecia areata is an autoimmune disease in which the immune system attacks the hair follicle, causing hair loss. T lymphocytes, and in particular certain T-cell subpopulations, play a central role in this process. IL-7 is a cytokine essential for the survival and expansion of T cells, while TSLP is involved in allergic and immune-type inflammation. The idea behind bempikibart is that switching off both upstream signals, by acting on the common receptor, may rebalance the immune response attacking the follicle, with the goal of enabling hair regrowth.

This mechanism is conceptually different from that of the drugs already approved in alopecia areata, the Janus kinase (JAK) inhibitors, which act downstream on a broader intracellular signalling cascade. Bempikibart instead acts further upstream and more selectively on one specific receptor. The difference in mechanism is one of the reasons why the observation of durability of the effect (see Part A) is considered particularly interesting: it could suggest an action that goes beyond simple temporary suppression of inflammation.

06 · The SIGNAL-AA study: Part A and Part B

SIGNAL-AA is the Phase 2a clinical study with which Q32 Bio evaluates bempikibart in alopecia areata. The study is organised into two parts, a Part A and a Part B, with different designs and objectives. Understanding the difference between the two is essential to read today’s data correctly.

Part A: durability and potential remittive effect

In Part A patients received bempikibart for 24 weeks of treatment. The company reported a reduction in the SALT score at week 24 and, notably to observers, durability of the effect: the benefit was maintained through week 36 and continued to be observed through week 55, despite dosing having been administered for only 24 weeks. This behaviour — improvement continuing even after stopping the drug — was described as a potential “remittive” effect, that is the possibility that the drug induces a more lasting change in the immune set-up rather than merely temporary suppression.^[5]

On the safety front, in Part A the company reported a favourable profile: no related adverse events of grade 3 or higher and no treatment-related viral infections. The Part A data were also presented at the 2025 American Academy of Dermatology (AAD) meeting.^[5]

The now-completed Part A open-label extension (OLE) enrolled 8 patients — responders, non-responders and placebo subjects from Part A — who had been off-drug for 26 to 55 weeks before re-dosing. Bempikibart was well tolerated with the longer dosing exposure and no new issues emerged; patients who retained hair at entry showed durable or further growth. The dataset reinforces the importance of a maintenance regimen and is consistent with the durability signal seen in the trial.^[9]

Part B: the design of today’s data

Part B is an open-label study that enrolled 33 patients with severe to very severe alopecia areata, with an episode duration of no more than four years. The dosing schedule involves 36 weeks in total: a loading phase of 200 mg weekly for the first 4 weeks, followed by 200 mg every 2 weeks for the subsequent 32 weeks. Follow-up extends to week 52. The endpoints are the mean percentage change in the SALT score and the proportion of subjects with SALT score improvements at week 36.^[4]

A relevant pharmacokinetic element: thanks to the loading phase, in Part B steady state (the equilibrium state of drug concentrations in the blood) was reached at least 9 weeks earlier than in Part A. The company also reported encouraging signs of clinical activity and disclosed that the first patient had been dosed in the open-label extension (OLE) phase of Part B. Enrollment in Part B had been completed on 21 October 2025.^[4]

07 · Alopecia areata: the disease and competitors

Alopecia areata is an autoimmune disease that causes hair loss, often in patches, and in the more severe forms can involve the entire scalp (alopecia totalis) or the entire body surface (alopecia universalis). According to the National Alopecia Areata Foundation, the disease affects roughly 700,000 people in the United States. It is a condition that can have a significant impact on quality of life, with meaningful psychological and social consequences, and for this reason it is an area of strong interest for the development of new drugs.

How it is measured: the SALT score

The standard tool for quantifying the extent of the disease is the SALT (Severity of Alopecia Tool) score. SALT expresses the percentage of the scalp without hair: a score of 100 indicates total absence of hair, while lower values indicate a smaller extent of loss. In clinical trials a response threshold such as SALT-20 is often used, indicating a score of 20 or below (no more than 20% of the scalp without hair): reaching it is considered a clinically meaningful outcome.

The competitive landscape

In the treatment of severe alopecia areata, drugs belonging to the Janus kinase (JAK) inhibitor class have already been approved, including baricitinib and ritlecitinib. These drugs have shown they can induce regrowth in a share of patients and represent the reference standard against which, sooner or later, any new agent will have to be compared. In addition to the approved JAK inhibitors, other approaches with different mechanisms are in development. In this context, bempikibart’s potential point of differentiation is its distinct mechanism (upstream blockade of IL-7Rα) and the durability of effect observed in Part A. This is a description of the landscape, not a comparative efficacy assessment, which would require head-to-head studies.

08 · Financial position and financings

The solidity of a clinical-stage biotech is measured above all by its cash and its ability to fund its activities to the next catalysts. As of 31 March 2026 Q32 Bio reported cash of $50.8 million. It should be noted that this figure excludes the $14.2 million gross received through the ATM (at-the-market) program after quarter-end. Company guidance of 5 May 2026 indicated a runway sufficient to fund operations into the first half of 2028; this guidance predates the late-May private placement, which further strengthened the position.^[2]

The first-quarter 2026 income statement

In the first quarter of 2026 Q32 Bio reported a net loss of $7.6 million, or $0.54 per share, an improvement from the loss of $11.0 million ($0.90 per share) in the first quarter of 2025. The reduction in the loss reflects the fall in expenses: research and development expenses declined to $3.2 million from $7.1 million a year earlier, while general and administrative expenses decreased to $4.5 million from $5.1 million in the first quarter of 2025. This trend is consistent with the February 2026 restructuring and the concentration on the bempikibart program alone. The company also reported venture debt of $8.2 million.^[2]

The fundraising operations: a dense sequence

Within a few months Q32 Bio completed a series of financing operations. In February 2026 it conducted a registered direct offering of $10.5 million, issuing 1,666,679 shares plus prefunded warrants for 1,025,654 shares, at a price of $3.90. Through the ATM program it then raised $14.2 million gross after the close of the first quarter. Finally, on 27 May 2026, it announced a $55 million private placement.^[3]

The May private placement is the most important of the sequence. It issued 6,725,000 shares at a price of $8.00, plus 150,000 prefunded warrants at $7.9999. The transaction was led by BVF Partners, with participation from RA Capital Management, OrbiMed and Atlas Venture. Morgan Stanley acted as lead placement agent and Oppenheimer as co-placement agent.^[3]

Dilution: the flip side

This sequence of raises has a cost for existing shareholders: dilution. The company’s share count has more than doubled since 2024. One aspect worth noting, however, is that the May private placement was carried out at $8.00, a price clearly above the $3.90 of the February offering: in jargon this is an “up round”, that is a capital increase carried out at a higher price than the previous one. This indicates that, between February and May, the perception of value among specialist investors improved. Dilution nevertheless remains a structural risk element, and the participation of leading specialist funds is a signal of interest that should be read together with its cost to existing shareholders.

09 · Management and investors

Q32 Bio is led by chief executive officer Jodie Morrison. The shareholder base reflects the presence of specialist investors in the biotechnology sector, who took part in particular in the $55 million private placement of May 2026: BVF Partners, which led the operation, together with RA Capital Management, OrbiMed and Atlas Venture. These are among the best-known and most active funds in financing clinical-stage biotechs.

The presence of specialist investors of this profile is often interpreted by observers as a signal of thorough due diligence on the clinical program, since these funds technically evaluate the data before committing capital. This reading should be handled with caution: the participation of well-known funds is not a guarantee of a positive study outcome, but it indicates qualified interest in the asset. On the investor relations front, Q32 Bio uses Argot Partners.

On the scientific side, the company was co-founded by Shelia Violette, Ph.D., who serves as Chief Scientific Officer; commenting on the topline, she described a significant and durable clinical benefit. The 36-week data were discussed on the company’s conference call with an independent key opinion leader, Arash Mostaghimi, MD, of Brigham and Women’s Hospital and Harvard Medical School, who characterised the results as robust in a population that also included patients previously treated with JAK inhibitors and pointed to bempikibart’s potential as a first-line treatment. Chief executive officer Jodie Morrison called the readout a significant milestone, with an efficacy and safety profile in line with the target and a differentiated, potentially more durable alternative to JAK inhibitors.^[9]

10 · Merlintrader Health Score

The Merlintrader Health Score is a synthetic measure of the financial and operational robustness (or fragility) of a biotech over a 12-18 month horizon. It combines five pillars with different weights. To be clear: it is not a buy or sell signal, it is not a judgement on the share price and it does not predict the outcome of clinical studies. It is only a structured way of reading how well equipped a company is to face the coming quarters.

The overall reading is that of a company with a relatively solid balance sheet for a clinical-stage small cap and a binary catalyst now delivered positively, but with a clear exposed flank on the dilution side, a direct consequence of the need to repeatedly finance itself in the market. The weighted average of the five pillars (0.3·4.5 + 0.3·4 + 0.2·2 + 0.1·3 + 0.1·4.5) equals 3.70. Once again: the score of 3.7 out of 5 is a snapshot of 12-18 month robustness, not an operational suggestion on the stock.

11 · Catalyst timeline

The sequence of events that brought Q32 Bio to today’s readout is useful to frame the stock’s moment. Below are the main milestones in chronological order.

12 · Risks and red flags

As with any clinical-stage biotech, the risk profile of Q32 Bio is high and concentrated. We list below the main points of attention, in a purely descriptive key.

13 · Bull / base / bear scenarios

The three scenarios that follow are purely descriptive and serve to illustrate how different data outcomes might be interpreted. They are not forecasts, contain no recommendations and indicate no price targets.

14 · Bottom line

Q32 Bio clears today’s readout as a clinical-stage biotech focused on a single asset, bempikibart, in a single indication, alopecia areata. The Part B 36-week topline came out positive, with the primary endpoint met (mean SALT reduction of 35.3% in the mITT population), a clean safety profile and durability signals off-drug. The company has a relatively solid balance sheet for its category, with cash reinforced by the $55 million private placement and a runway guided into the first half of 2028, but it carries the weight of repeated dilution and the structural risk of depending on a single program as it moves toward a registration-directed program in the first half of 2027.

15 · Frequently asked questions

Merlintrader resources

16 · Sources

1. Q32 Bio — press release announcing the 36-week Part B SIGNAL-AA topline results and the conference call.
2. Q32 Bio — first-quarter 2026 financial results and corporate update.
3. Q32 Bio — announcement of the $55 million private placement financing.
4. Q32 Bio — completion of enrollment in Part B of the SIGNAL-AA Phase 2a study of bempikibart.
5. Q32 Bio — SIGNAL-AA Part A results presented at the 2025 American Academy of Dermatology meeting.
6. SEC — Q32 Bio, first-quarter 2026 Form 10-Q.
7. Q32 Bio — closing of the merger with Homology Medicines and $42 million private placement.
8. Q32 Bio — company website (Investors section).
9. Q32 Bio — press release “Q32 Bio Announces Positive 36-Week Topline Results…” from Part B of the SIGNAL-AA study (13 July 2026).

Data verified against primary sources (company press releases on ir.q32bio.com and PRNewswire, SEC filings) as of the publication date. The positive 36-week Part B topline results were reported by Q32 Bio on 13 July 2026 and are summarised in section 03.